A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis
This open-label multicenter phase-IIIb trial was conducted at 47 German institutions; the first 25 patients analyzed in this safety analysis were recruited in 10 centers.
Background
Treosulfan,
an alkylating agent, has demonstrated activity in recurrent ovarian
carcinoma. It is equieffective as oral (p.o.)
and intravenous (i.v.) formulation. To explore the
preference and compliance of elderly patients regarding p.o. or i.v.
treosulfan
for the treatment of relapsed ovarian carcinoma, women
aged 65 years or older were included in this prospective multicenter
study. Since elderly patients usually have several
concomitant diseases and experience more treatment toxicity, an interim
safety analysis was planned and performed after 25
patients finished therapy to assess the tolerability of the treatment
regimens.
Table 1 - 6
Conflict of interest The trial was supported by Medac GmbH.
Table 1 - 6
- Patient characteristics
- Concomitant diseases
- Treatment delivery
- Reasons for early therapy discontinuation [less than 12 cycles (i.v.) or 12 months of therapy
- Non-hematological toxicities: highest grade per patient (in alphabetic order)
- Hematological toxicities: highest grade per patient
"In summary, the observed toxicities were in the same range as reported in previous studies with significantly younger patients
and less comorbidity or with old women having received fewer previous lines of chemotherapy.
There were no unexpected hematological or
non-hematological toxicities. Based on this safety analysis, treosulfan
proved to
be a safe and tolerable therapeutic option in elderly,
heavily pretreated patients and the next step of study recruitment
was initiated. Of note, the majority of patients in the
interim safety population chose i.v. treosulfan over the oral
application.
Detailed analysis after completion of the trial will
hopefully yield new insight into therapy preference and compliance of
elderly patients with recurrent ovarian cancer."